Foresite Capital
Signal active
Investment Firm
Overview
Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.
Highlights
Founded
2011
Industry
Financial Services
Employees
51-100
Investment
163
Lead Investment
49
Exits
60
Stages
Early Stage Venture, Late Stage Venture, Seed, Private Equity
Investor Type
Private Equity Firm
Location
United States, North America
Contact Information
Social
Profile Resume
Foresite Capital, established in 2011 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed, Private Equity investments across Biotechnology, Medical, Medical Device, Venture Capital, Life Science, Financial Services, Finance, FinTech, Health Care, Health Diagnostics. The organization boasts a portfolio of 158 investments, with an average round size of $119.2M and 60 successful exits. Their recent investments include Tarsa Therapeutics, Quaker BioVentures, Marker, Novo Holdings, MVM Life Science Partners. The highest investment round they participated in was $2107.9B. Among their most notable exits are Tarsa Therapeutics and Quaker BioVentures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Foresite Capital has made 163 investments. Their most recent investment was on Jul 30, 2024, when Foresight Diagnostics raised $33.0M.
Foresite Capital has made 39 diversity investments. Their most recent diversity investment was on Jul 11, 2024, when Element Biosciences raised $277.0M.
investments
163
Diversity investments
39
Lead investments
49
Number of exits
60
Investments
163
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jul 16, 2024 | Thyme Care | Health Care | 55.0M |
| Jul 23, 2024 | - | - | 165.0M |
| Jul 29, 2024 | Spear Bio | Biotechnology | 45.0M |
| Jul 30, 2024 | Foresight Diagnostics | Biotechnology | 33.0M |
Exits
60
Funding Timeline
Funding rounds
163
Investors
0
Funds
8
Funding Rounds
163
Foresite Capital has raised 163 rounds. Their latest funding was raised on Jul 30, 2024 from a Series B - Foresight Diagnostics round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jul 16, 2024 | Series C - Thyme Care | - | 55.0M | - |
| Jul 23, 2024 | Series A - Third Arc Bio | - | 165.0M | - |
| Jul 29, 2024 | Series A - Spear Bio | - | 45.0M | - |
| Jul 30, 2024 | Series B - Foresight Diagnostics | - | 33.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.